Literature DB >> 1648442

Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.

P A Andrews1, S C Mann, H H Huynh, K D Albright.   

Abstract

We examined the importance of the Na+, K(+)-ATPase in cisplatin (DDP) accumulation in 2008 human ovarian carcinoma cells and describe changes in the Na+, K(+)-ATPase in DDP-resistant cells with DDP accumulation defects. Approximately 50% of DDP accumulation was inhibitable by ouabain. DDP accumulation into 2008 cells could be maximally inhibited when cells were preincubated with ouabain for 1 h prior to DDP exposure. The half-maximal inhibition was obtained with 0.13 microM ouabain. Similar inhibition of DDP accumulation was obtained when the Na+, K(+)-ATPase was blocked by ATP depletion or by incubating cells in K(+)-free medium. This same percentage of DDP accumulation was Na+ dependent and varied directly with Na+ concentration. These effects on DDP accumulation could be detected as early as 1 min after the imposition of 0-trans conditions, strongly suggesting that the inhibition was due to modulation of a drug influx step. The Na+, K(+)-ATPase in 2008/DDP cells had a similar KD for ouabain binding and 36% less Na+, K(+)-ATPase molecules/mg of protein than 2008 cells. 2008/DDP cells 2.3 +/- 0.2 (SE, n = 3) fold cross-resistant to ouabain in a continuous exposure clonogenic assay. Despite these changes in the Na+, K(+)-ATPase, the net basal Na+, K(+)-ATPase activity was the same in sensitive and DDP-resistant cells as determined by ouabain-inhibitable 86Rb+ influx. The basal Na+ levels were also similar in the sensitive and resistant cells. These data suggest that DDP accumulation is partially Na+ dependent and that, therefore, the Na+, K(+)-ATPase which maintains the Na+ gradient may play an important role in determining how much DDP enters cells. Whether there is a causal link between the changes in the Na+, K+-ATPase in DDP-resistant cells and their DDP accumulation defect is not yet known.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648442

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Contribution of intracellular ATP to cisplatin resistance of tumor cells.

Authors:  Verena Schneider; Michaela L Krieger; Gerd Bendas; Ulrich Jaehde; Ganna V Kalayda
Journal:  J Biol Inorg Chem       Date:  2012-11-25       Impact factor: 3.358

2.  Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid, in single cells.

Authors:  F Sureau; F Moreau; J M Millot; M Manfait; B Allard; J Aubard; M A Schwaller
Journal:  Biophys J       Date:  1993-11       Impact factor: 4.033

3.  Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.

Authors:  K Son; L Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.

Authors:  E Kimura; R E Enns; F Thiebaut; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

6.  Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level.

Authors:  Verena Schneider; Selim Chaib; Claudia Spanier; Mandy Knapp; Violeta Moscvin; Laura Scordovillo; Alessandra Ewertz; Ulrich Jaehde; Ganna V Kalayda
Journal:  AAPS J       Date:  2017-11-30       Impact factor: 4.009

7.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Authors:  P Naredi; D D Heath; R E Enns; S B Howell
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

9.  Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.

Authors:  Ramakumar Tummala; Daniel Wolle; Sonali P Barwe; Valerie B Sampson; Ayyappan K Rajasekaran; Lakshmi Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.